Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089517 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
A Phase 2 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 449
- Enrollment target
NCT01089517: Completed Phase 2 study, sponsored by Ophthotech Corporation.
NCT01089517 is a Phase 2 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 449 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01089517, a Phase 2 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 449 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Primary Outcome
The primary efficacy endpoint is the mean change in visual acuity from baseline at the Week 24 visit
Interventions
- DRUG Lucentis
- DRUG E10030 plus Lucentis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT01089517 record still lists
NCT01089517 is an interventional study that assigns participants to a tested intervention. The registered 449 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher).
The record links to 0 conditions, and to 2 interventions - of which Lucentis is the first listed.
NCT01089517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01089517 about?
NCT01089517 is a clinical study titled "A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration". The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT01089517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 449 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01089517?
The interventions under investigation include: Lucentis (DRUG), E10030 plus Lucentis (DRUG).
Who is sponsoring clinical trial NCT01089517?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01089517's enrollment target sits among peer trials
449 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia